Company Description
IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases.
It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.
IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies.
The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010.
IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
| Country | United States |
| IPO Date | Sep 18, 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 224 |
| CEO | Fred M. Schwarzer J.D. |
Contact Details
Address: 325 E Middlefield Road Mountain View, California 94043 United States | |
| Phone | 650-965-7873 |
| Website | igmbio.com |
Stock Details
| Ticker Symbol | IGMS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $16.00 |
| CIK Code | 0001496323 |
| CUSIP Number | 449585108 |
| ISIN Number | US4495851085 |
| Employer ID | 77-0349194 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Fred M. Schwarzer J.D. | Chief Executive Officer, President and Director |
| Dr. Bruce A. Keyt Ph.D. | Chief Scientific Officer |
| Dr. Chris H. Takimoto FACP, M.D., Ph.D. | Chief Medical Officer |
| Misbah Tahir | Chief Financial Officer |
| TS Harigopal | Senior Vice President of Group Operations |
| Steven Weber | Senior Vice President, Corporate Controller and Principal Accounting Officer |
| Paul C. Graffagnino | Senior Vice President of Legal Affairs |
| Suzette Tauber | Chief Human Resources Officer |
| Dr. Angus M. Sinclair Ph.D. | Senior Vice President of Immuno-Oncology |
| Dr. Lisa L. Decker Ph.D. | Chief Business Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 17, 2024 | 8-K | Current Report |
| Apr 15, 2024 | PRE 14A | Other preliminary proxy statements |
| Mar 28, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 13, 2024 | 144 | Filing |
| Mar 13, 2024 | 144 | Filing |
| Mar 13, 2024 | 144 | Filing |
| Mar 7, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 7, 2024 | 8-K | Current Report |
| Mar 7, 2024 | 10-K | Annual Report |
| Feb 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |